文献速递妇科肿瘤

聚(ADP-核糖)聚合酶抑制剂时代晚期上皮性卵巢癌的肿瘤细胞减灭术——是时候转变范式了吗?系统综述与荟萃分析

Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era-Is it time for a new paradigm shift? A systematic review and meta-analysis.
PubMed 文献 · Eur J Cancer · 2023-04-05

该系统综述与荟萃分析纳入6项III期随机对照试验(SOLO 1、PAOLA 1、PRIMA、PRIME、ATHENA-MONO、VELIA),评估PARPi一线维持治疗按术后残留病灶状态对PFS的效应。结果显示,肉眼残留病灶患者接受PARPi维持治疗较安慰剂显著改善PFS(汇总HR 0.55;95%CI 0.44-0.68),与完全肉眼切除患者(汇总HR 0.53;95%CI 0.41-0.67)幅度相当。作者结论认为肉眼残留病灶患者从PARPi获益程度与完全肉眼切除者相同,但完全肉眼切除后接受PARPi者PFS率最优,因此在PARPi时代追求完全细胞减灭仍然有效。

要点

  • 肉眼残留病灶患者接受PARPi维持治疗较安慰剂显著改善PFS(汇总HR 0.55;95%CI 0.44-0.68)。
  • 完全肉眼切除患者接受PARPi的PFS获益幅度与肉眼残留病灶者相当(汇总HR 0.53;95%CI 0.41-0.67)。
  • 完全肉眼切除后接受PARPi者PFS率最优,作者认为PARPi时代追求完全细胞减灭仍然有效。

核心结论

  • 肉眼残留病灶患者从PARPi获益程度与完全肉眼切除者相同。
  • 完全肉眼切除后接受PARPi者PFS率最优,因此PARPi时代追求完全细胞减灭仍然有效。

研究设计与样本

  • 系统综述与荟萃分析,按照PRISMA指南进行,检索Medline/PubMed、Embase和Cochrane数据库及会议摘要至2023年3月18日。
  • 共纳入6项III期随机对照试验:SOLO 1、PAOLA 1、PRIMA、PRIME、ATHENA-MONO和VELIA。
  • 提取PFS的HR及其95%CI,并按术后残留病灶进行亚组分析以考察PARPi的效应。

主要发现

  • 肉眼残留病灶患者接受PARPi维持治疗较安慰剂显著改善PFS(汇总HR 0.55;95%CI 0.44-0.68)。
  • 完全肉眼切除患者接受PARPi的PFS获益幅度与肉眼残留病灶者相当(汇总HR 0.53;95%CI 0.41-0.67)。
  • 完全肉眼切除后接受PARPi的患者PFS率最优。

临床怎么用

  • 作者认为,在PARPi时代追求达到完全细胞减灭仍然有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In patients with newly diagnosed advanced high-grade serous and endometrioid epithelial ovarian cancer (EOC) first-line maintenance therapy with poly(ADP-ribose) polymerase inhibitors (PARPi) tremendously improved progression-free survival (PFS). Yet, data on the effect of PARPi in proportion to postoperative residual disease status were lacking. MATERIAL AND METHODS: A systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items of Systematic reviews and Meta-Analysis (PRISMA) guidelines. We searched Medline/Pubmed, Embase and Cochrane databases as well as meeting abstracts until 18th March 2023. Hazard ratios (HRs) alongside their 95% confidence intervals (CIs) for PFS were extracted from the studies. A subgroup analysis was conducted to examine the effect of PARPi according to postoperative residual disease. RESULTS: A total of six phase III randomised controlled trials were included and comprised SOLO 1, PAOLA 1, PRIMA, PRIME, ATHENA-MONO and VELIA. Patients who received PARPi following complete gross resection showed greatest PFS benefit. Compared with placebo, maintenance with PARPi significantly improved PFS in patients with macroscopic residual disease (pooled HR 0.55; 95% CI 0.44-0.68). This magnitude was comparable to that found in patients with complete gross resection (pooled HR 0.53; 95% CI 0.41-0.67). CONCLUSIONS: Patients with macroscopic residual disease benefit from PARPi at the same extent as cases with complete gross resection. However, patients with complete gross resection who were treated with PARPi show the most favourable PFS rates. Hence, the pursuit of achieving complete cytoreduction remains valid in the PARPi era.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Peters ITA, Marchetti C, De Palma A, et al. Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era-Is it time for a new paradigm shift? A systematic review and meta-analysis. Eur J Cancer. 2023. PMID: 37130463. doi:10.1016/j.ejca.2023.03.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。